Aureon completes early study with AstraZeneca
-
- September
- 6
YONKERS — Aureon Laboratories Inc. announced today the successful completion of an initial study with AstraZeneca designed to identify patients with non-small-cell lung cancer that could benefit from treatment with AstraZeneca’s Iressa.
Aureon’s System Pathology approach is intended to enable medical professionals to predict how patients will respond to specific drugs. It uses computer-based image analysis of tumor tissue samples along with mathematical tools, providing information to cancer centers and physicians. Aureon’s proprietary method could lead to more effective, personalized treatment and shorter, more-focused clinical trials, the company said.
“This project is only the first step in what we believe will be a fruitful area of research,� Aureon President and Chief Executive Officer Vijay Aggarwal said in a written statement. “This project validates our technology in yet another setting: pharmaceutical development. Finally, it is an excellent next step in Aureon’s development as a company after our 2006 launch of Prostate Px for prostate cancer recurrence prediction.�
This entry was posted
on Thursday, September 6th, 2007 at 3:39 pm by Alison Bert.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
